42 results about "Myocardial apoptosis" patented technology

The invention discloses an application of LiCl in preparation of a drug for resisting myocardial apoptosis induced by excessive accumulation of lipids. Experiments prove that LiCl can effectively inhibit myocardial apoptosis induced by long-chain saturated fatty acid palmitate, specifically, LiCl inhibits cutting of palmitate induced apoptosis executor caspase 3 precursors, and the apoptosis rate of cells and pyknosis of nucleus chromatin are remarkably reduced; the experiments further determine that 40 mM concentration can be taken as drug concentration for effectively and specifically inhibiting palmitate induced H9c2 myocardial apoptosis by LiCl, and LiCl is expected to be applied to the preparation of the drug for treating the myocardial apoptosis induced by excessive accumulation of the lipids accompanied by diseases such as obesity, diabetes mellitus and the like in clinical research and has broad scientific research and clinical development prospect.

The invention relates to the field of treatment of sepsis heart failure, in particular to a traditional Chinese medicine composition for treating sepsis heart failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition consists of 25-35 parts of radix astragali, 15-25 parts of poria cocos, 15-25 parts of radix salviae miltiorrhizae, 5-15 parts of Chinese magnoliavine fruits, 10-20 parts of radix ophiopogonis, 10-20 parts of tansymustard seeds, 15-25 parts of motherwort and 35-55 parts of princesplume ladysthumb fruits and fructus aurantii, wherein the mass ratio of the added princesplume ladysthumb fruits to the added fructus aurantii is 1.25-3.5 to 1. The lethality caused by sepsis can be reduced, the myocardial damage canbe reduced, and the traditional Chinese medicine composition can resist inflammation, restrain myocardial apoptosis and the like, and has better treatment effects on the sepsis heart failure.

The invention discloses an application of an AVEN gene in ischemic heart disease. Through analysis, the invention finds that the AVEN gene is obviously reduced in myocardial infarction patients and mouse myocardial infarction models, which may be an important reason for myocardial apoptosis and heart failure. The AVEN is overexpressed in a mouse myocardial infarction model by using the adeno-associated virus, and the result shows that the overexpression of the AVEN can inhibit myocardial cell apoptosis and obviously improve the left ventricular function. According to the application of the AVEN gene in preventing and treating the ischemic heart disease, AVEN adeno-associated virus gene therapy is given to a patient suffering from myocardial infarction clinically, myocardial cell apoptosis can be inhibited, the cardiac contraction and relaxation functions are improved, and the living quality and long-term prognosis of the patient are improved; a new target and strategy are provided for clinically preventing and treating the ischemic heart disease.

The invention discloses small molecular polypeptide inhibiting MIRI and a vector and application thereof. A bioengineering technology is utilized, a section of sequence corresponding to polypeptide analogue is genetically recombined to a p3XFLAG-CMV eukaryotic expression vector; after it is proved that recombination is successful through enzyme digestion and sequential analysis, plasmid corresponding to the eukaryotic expression polypeptide analogue is transfected into myocardium cells, protein expression of polypeptide is proved through immunoblotting, and polypeptide recombination is achieved. It is proved through co-immunoprecipitation that the polypeptide analogue can promote interaction of PDCD4 and Nrf2, it is shown through cell biology experiments that the polypeptide analogue has the capacity of inhibiting myocardium cell apoptosis caused by myocardial ischemia and reperfusion injuries and the functions of resisting oxidative stress and apoptosis of the myocardium cells and inhibiting occurrence and development of MIRI.

The invention relates to compounds of the general formula I, or their isomers, medicinal salts and solvates. The invention also relates to compositions containing the compounds shown of the general formula I, or their isomers, medicinal salts and solvates, and pharmaceutically acceptable carriers, excipients or diluents. The invention further relates to uses of the compounds shown of the general formula I, or their isomers, medicinal salts and solvates in resisting cell apoptosis and preventing or treating of diseases or symptoms related to cell apoptosis, and especially in protecting cardiac muscle cells and preventing or treating diseases or symptoms related to cardiac muscle cell apoptosis.

The invention discloses application of human amniotic mesenchymal stem cells in preparation of a preparation for treating a myocardial ischemia reperfusion injury generated after cardiopulmonary bypass.In the myocardial ischemia reperfusion process after the cardiopulmonary bypass, the human amniotic mesenchymal stem cells can effectively prevent myocardial cells from being injured in myocardial ischemia reperfusion, obviously improve the cardiac functions, lower the levels of myocardial injury specific marker protein lactic dehydrogenase, creatine kinase isoenzyme and troponin I, lower the levels of a plasma inflammatory factor interleukin-8 and a tumor mecrosis factor-alpha, increase the content of the plasma inflammatory factor interleukin-10, obviously improve pathological changes of the myocardial tissue, reduce myocardial cell apoptosis, lower the expression level of cell apoptosis promoting protein, increase the expression quantity of anti-apoptoasis protein and can protect the functions of myocardial cell mitochondria.By preparing the human amniotic mesenchymal stem cells into an injection for treatment on the myocardial ischemia reperfusion injury generated after the cardiopulmonary bypass, the cardiac functions can be effectively protected, and postoperative complications of the cardiopulmonary bypass are relieved.

The invention belongs to the field of molecular biology, and provides a preparation for detecting myocardial cell excessive apoptosis and a method for detecting myocardial cell excessive apoptosis. The invention also provides an application of the MST1 gene expression plasmid in preparation of a preparation for improving the myocardial cell apoptosis rate in a high-glucose environment, an application of the siRNA interference plasmid of the MST1 gene in preparation of a preparation for reducing the myocardial cell apoptosis rate in the high-glucose environment, and a method for regulating andcontrolling the myocardial cell apoptosis rate. By utilizing the relationship between the MST1 gene and myocardial cell excessive apoptosis, especially myocardial cell excessive apoptosis in a high-glucose environment, the preparation for detecting myocardial cell excessive apoptosis provided by the invention can be used for efficiently and accurately detecting the apoptosis condition of myocardial cells in the high-glucose environment; and therefore, whether excessive apoptosis occurs to cardiac muscle cells cultured in vitro or development of heart tissue during fetal development in a motherbody or not is accurately judged.

The invention discloses new application of gynesine, namely application of the gynesine in preparing a medicine or food for treating or preventing hypoxic damage, and the medicine or the food preparedfrom the gynesine and used for treating or preventing hypoxic damage. The research finds that the gynesine has a function of treating or preventing hypoxic damage, and can be used for preparing the medicine or the food for treating or preventing hypoxic damage; a cell experiment and an animal experiment prove that the gynesine can be beneficial to protecting hypoxic nerve cell damage, reducing myocardial apoptosis caused by hypoxia, prolonging the survival time of rats in a normal pressure anoxia tolerance test, and increasing the survival rate of the rats in an acute low pressure hypoxia test.

The invention provides a miRNA-140 inhibitor and applications thereof, wherein a sequence of the inhibitor has at least 90% of homology with a nucleotide sequence showing in the following SEQ ID NO:1: 5'-CUACCAUAGGGUAAAACCACUG-3', wherein each basic group is modified by 2'-O-methyl; and the miRNA-140 inhibitor is used for preparing a medicament or a kit for diagnosing, preventing, treating and / or prognostically evaluating heart diseases. The miRNA-140 inhibitor is changed in treatment of myocardial ischemia injury and myocardial apoptosis and has a myocardial preservation effect.

The invention discloses a myocardial ischemia re-perfusion injury marker circRNA and application thereof, and belongs to the technical field of biology. The invention proves that circ-Fbxl5 can form a sponge adsorption relationship with miRNA-146a in myocardial cells so as to relieve the protective effect of the miRNA-146a on myocardial ischemia re-perfusion injury, and a shRNA (short hairpin ribonucleic acid) capable of knocking down circ-Fbxl5 expression is designed. Through detection, the prepared shRNA can knock down circ-Fbxl5 expression quantity, the infarct area of a myocardial ischemia re-perfusion mouse can be remarkably reduced, the myocardial apoptosis level is reduced, and it is proved that the prepared shRNA can be applied to the medicine for preventing and treating myocardial ischemia re-perfusion injury.

The invention discloses application of irisin in the preparation of drugs for preventing myocardial ischemia reperfusion injuries. Experimental results show that irisin can decrease the myocardial infarction area caused by ischemia reperfusion, reduce the increase of the contents of lactate dehydrogenase (LDH), troponin (cTnI), creatine kinase (CK), and other myocardial enzyme markers caused by ischemia reperfusion, meanwhile reducing the inflammatory response, myocardial apoptosis, and oxidative stress response caused by myocardial ischemia reperfusion, promote peroxysome proliferator-activated receptor γ nuclear translocation, and inhibit nuclear transcription factor NF-κB nuclear translocation and accordingly decrease myocardial structure injuries and load increase caused by ischemia reperfusion. Therefore, irisin can be used for preventing and decreasing myocardial reperfusion injuries and has important clinical significance on the treatment of myocardial ischemia.